Top

Published in:

Open Access 01-02-2019 | Original Article

Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma

Published in: Virchows Archiv | Issue 2/2019

Abstract

Molecular testing for mutations in the EGFR gene is commonplace for patients with non-small cell lung cancer (NSCLC). These patients are often very sick and management decisions need to be made urgently. In many cases, the results of molecular testing are needed the same day, in order to start targeted therapy and allow maximum benefit for patients. The Idylla™ EGFR Mutation Test offers rapid results within three hours of requesting. This study aimed to assess the concordance of Idylla™ EGFR Mutation Test results with current standard tests. Forty formalin-fixed, paraffin-embedded NSCLC tumour cases (20 EGFR mutant and EGFR 20 wild type) were analysed by the Idylla™ EGFR Mutation Test (CE-IVD) and compared with PCR and NGS methodologies. The overall concordance between Idylla™ and standard testing was 92.5% (95% CI 80.14% to 97.42%) and the specificity of Idylla™ was 100% (95% CI 83.89% to 100%). The sensitivity was affected by loss of tumour content in tissue blocks in a small number of NGS cases; however, comparing Idylla™ with PCR alone, there was 100% concordance (95% CI 89.85% to 100%). The Idylla™ EGFR Mutation Test shows comparative accuracy to routine PCR testing for the most common EGFR mutations in NSCLC. The Idylla™ also offers significantly reduced turn-around times compared with existing modalities and therefore the platform would be a useful addition to many molecular diagnostics units.

CRUK. Lung cancer statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer. (cited 2018 March 1st)

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14(8):535–546CrossRefPubMedPubMedCentral

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung Cancer to Gefitinib. N Engl J Med 350(21):2129–2139CrossRefPubMed

Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R (2012) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol

NICE. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. Available from: https://www.nice.org.uk/guidance/dg9/chapter/3-Clinical-need-and-practice. (cited 2018, March 1st)

Thermo Fisher Scientific Inc. Ion AmpliSeq™ Cancer Hotspot Panel v2. Available from: http://www.thermofisher.com/order/catalog/product/4475346. (cited 2016, November 28th)

Biocartis. About Idylla. Available from: https://www.biocartis.com/idylla. (cited 2016, November 28th)

Thermo Fisher Scientific Inc. Ion Torrent. Available from: https://www.thermofisher.com/uk/en/home/brands/ion-torrent.html. (cited 2016, November 28th)

Biocartis. Idylla™ EGFR Mutation Assay (CE-IVD). Available from: https://biocartis.com/idylla-egfr-mutation-test. (cited 2018, March 1st)

10.

Colling R, Wang LM, Soilleux E (2016) Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study. J Clin Pathol 69(5):398-402. https://doi.org/10.1136/jclinpath-2015-203345

11.

Solassol J, Vendrell J, Markl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pages JC, Sillekens P (2016) Multi-center evaluation of the fully automated PCR-based Idylla KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal Cancer. PLoS One 11(9):e0163444CrossRefPubMedPubMedCentral

12.

de Biase D, de Luca C, Gragnano G, Visani M, Bellevicine C, Malapelle U, Tallini G, Troncone G (2016) Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. J Clin Pathol. https://doi.org/10.1136/jclinpath-2016-203696

13.

Harlé A, Salleron J, Franczak C, Dubois C, Filhine-Tressarieu P, Leroux A, Merlin JL (2016) Detection of BRAF mutations using a fully automated platform and comparison with high resolution melting, real-time allele specific amplification, immunohistochemistry and next generation sequencing assays, for patients with metastatic melanoma. PLoS One 11(4):e0153576CrossRefPubMedPubMedCentral

14.

Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F (2016) BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated molecular diagnostics system. Mol Cancer Ther 15(6):1397–1404CrossRefPubMed

15.

Schiefer AI, Parlow L, Gabler L, Mesteri I, Koperek O, von Deimling A, Streubel B, Preusser M, Lehmann A, Kellner U, Pauwels P, Lambin S, Dietel M, Hummel M, Klauschen F, Birner P, Mobs M (2016) Multicenter evaluation of a novel automated rapid detection system of BRAF status in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 18(3):370–377CrossRefPubMed

16.

Uguen A, Troncone G (2018) A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day. J Clin Pathol 71:757–762CrossRefPubMed

17.

Thomas De Montpreville V, Ghigna MR, Lacroix L, Lemoine A, Besse B, Mercier O, Fadel E, Dorfmuller P, Le Chevalier T (2017) EGFR and KRAS molecular genotyping for pulmonary carcinomas: feasibility of a simple and rapid technique implementable in any department of pathology. Pathol Res Pract 213(7):793–798CrossRefPubMed

18.

De Luca C, Gragnano G, Pisapia P, Vigliar E, Malapelle U, Bellevicine C, Troncone G (2017) EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR mutation assay. J Clin Pathol 70(4):295–300CrossRefPubMed

19.

Lambros L, Caumont C, Guibourg B, Barel F, Quintin-Roue I, Marcorelles P, Merlio JP, Uguen A (2017) Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day. J Clin Pathol 70(6):544–549CrossRefPubMed

20.

Ilie M, Butori C, Lassalle S, Heeke S, Piton N, Sabourin J-C, Tanga V, Washetine K, Long-Mira E, Maitre P, Yazbeck N, Bordone O, Lespinet V, Leroy S, Cohen C, Mouroux J, Marquette CH, Hofman V, Hofman P (2017) Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget 8(61):103055–103062CrossRefPubMedPubMedCentral

21.

The Royal College Pathologists. Dataset for lung cancer histopathology reports, 5th edn. Available from: https://www.rcpath.org/resourceLibrary/g048-lungdataset-sep16-pdf.html. (cited 2018, March 1st)

22.

Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M (2013) Molecular testing guideline for selection of lung Cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8(7):823–859CrossRefPubMedPubMedCentral

23.

Sullivan I, Planchard D (2016) ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 8(1):32–47CrossRefPubMedPubMedCentral

24.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469(5):489–503CrossRefPubMedPubMedCentral

25.

Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K, Lal R, Lewanski C, Navani N, Nicholson AG, Nicolson M, Summers Y (2016) PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 69(2):177–186CrossRefPubMed

26.

My Cancer Genome. EGFR c.2303G>T (S768I) Mutation in lung cancer. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/egfr/348/. (cited 2018, March 1st)

27.

My Cancer Genome. EGFR c.2582T>A (L861Q) Mutation in non-small cell lung cancer. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/egfr/6/. (cited 2018, March 1st)

28.

My Cancer Genome. EGFR c.2369C>T (T790M) Mutation in non-small cell lung cancer. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/egfr/4/. (cited 2018, March 1st)

29.

Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M (2010) Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 40(11):1105–1109CrossRefPubMed

30.

Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277(2):301–308CrossRefPubMed

31.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73CrossRefPubMedPubMedCentral

32.

Soilleux EJ, Wotherspoon A, Eyre TA, Clifford R, Cabes M, Schuh AH (2016) Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology 69(6):1066–1076CrossRefPubMed

33.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A (2016) NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol 175(1):43–54CrossRefPubMed

Title: Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma
Publication date: 01-02-2019
Published in: Virchows Archiv / Issue 2/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2486-y

ACC 2024 Congress

Springer Medicine

Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Cerebrovascular pathology in cerebral amyloid angiopathy presenting as intracerebral haemorrhage

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder

Implementation of modern tools in autopsy practice—the way towards contemporary postmortal diagnostics

Digital quantification of KI-67 in breast cancer

Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing

Correction to: Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes